A Randomized Phase 2 Study of the Triplet Combination of Ridaforolimus (Rida), Dalotuzumab (Dalo) and Exemestane (Ex) Compared to the Ridaforolimus, Exemestane Doublet in High Proliferation, Estrogen Receptor Positive (Er plus ) Advanced Breast Cancer

AuthID
 P-00P-7TZ
16
Author(s)
Tredan, O
·
Ro, J
·
Morales, SM
·
Musolina, A
·
Afonso, N
·
Ferreira, M
·
Park, KH
·
Cortes, J
·
Tan, AR
·
Blum, JL
·
Eaton, L
·
Mauro, D
·
Gause, C
·
Im, E
·
Baselga, J
Document Type
Abstract
Year published
2013
Published
in CANCER RESEARCH, ISSN: 0008-5472
Volume: 73
Indexing
Wos®
Google Scholar®
Publication Identifiers
Wos: WOS:000209496900077
Source Identifiers
ISSN: 0008-5472
Export Publication Metadata
Marked List
 Add to Marked List
Info
At this moment we don't have any links to full text documens.

A place for researchers and their institutions

Useful Links

Get Help

© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service